Meshul C K, Tan S E
Research Service, V.A. Medical Center, Portland, Oregon.
Synapse. 1994 Nov;18(3):205-17. doi: 10.1002/syn.890180306.
Administration of haloperidol for 2 weeks causes an increase within the caudate nucleus of asymmetrical synapses associated with a discontinuous or perforated, postsynaptic density (PSD) [Meshul et al. (1992), Psychopharmacology, 106:45-52; Meshul et al. (1992), Neuropsychopharmacology, 7:285-293]. Coadministration of the N-methyl-D-aspartate noncompetitive antagonist, MK-801, with haloperidol blocked the increase in striatal synapses containing a perforated PSD [Meshul et al. (1994), Brain Res., 648:181-195]. Examination of the caudate using immuno-gold electron microscopy revealed the vast majority (90%) of asymmetrical synapses were labelled with a glutamate antibody [Meshul et al. (1994), Brain Res., 648:181-195]. The purpose of this study was to determine if there were any changes in the density of glutamate immunoreactivity within presynaptic terminals of asymmetric synapses within the striatum following treatment with haloperidol for 1 month that would correlate with the previously observed increase in synapses with perforated PSDs. We also determined the activity of striatal calcium/calmodulin kinase II (CaMK II), an enzyme known to be localized within the synaptic region, after administration of haloperidol. We report here that haloperidol causes an increase in the activity of CaMK II and a decrease in the density of immuno-gold labelling for glutamate within the nerve terminals of asymmetrical synapses containing a perforated or nonperforated PSD. These results are consistent with the hypothesis that the haloperidol-induced increase in activity of CaMK II and the increase in glutamate release, as suggested by the decrease in presynaptic glutamate immunoreactivity, may ultimately lead to an increase in the number of synapses displaying a perforated PSD. These results support the speculation that the haloperidol-induced increase in synapses containing a perforated PSD may be associated with enhanced activity at excitatory synapses.
给予氟哌啶醇2周会导致尾状核内不对称突触数量增加,这些突触伴有不连续或穿孔的突触后致密物(PSD)[Meshul等人(1992年),《精神药理学》,106:45 - 52;Meshul等人(1992年),《神经精神药理学》,7:285 - 293]。将N - 甲基 - D - 天冬氨酸非竞争性拮抗剂MK - 801与氟哌啶醇联合使用,可阻止含有穿孔PSD的纹状体突触数量增加[Meshul等人(1994年),《脑研究》,648:181 - 195]。使用免疫金电子显微镜检查尾状核发现,绝大多数(90%)不对称突触被谷氨酸抗体标记[Meshul等人(1994年),《脑研究》,648:181 - 195]。本研究的目的是确定在用氟哌啶醇治疗1个月后,纹状体内不对称突触的突触前终末内谷氨酸免疫反应性密度是否有任何变化,这些变化是否与先前观察到的含有穿孔PSD的突触数量增加相关。我们还测定了给予氟哌啶醇后纹状体钙/钙调蛋白激酶II(CaMK II)的活性,该酶已知定位于突触区域。我们在此报告,氟哌啶醇会导致CaMK II活性增加,并且在含有穿孔或未穿孔PSD的不对称突触的神经终末内,谷氨酸的免疫金标记密度降低。这些结果与以下假设一致:氟哌啶醇诱导的CaMK II活性增加以及突触前谷氨酸免疫反应性降低所暗示的谷氨酸释放增加,最终可能导致显示穿孔PSD的突触数量增加。这些结果支持了以下推测:氟哌啶醇诱导的含有穿孔PSD的突触增加可能与兴奋性突触处增强的活性有关。